Drug Profile
Research programme: inflammatory pain therapeutics - Arissa Pharma
Alternative Names: AP 2300; AP 2500; AP 2900Latest Information Update: 04 Sep 2023
Price :
$50
*
At a glance
- Originator Arissa Pharma
- Class Nonsteroidal anti-inflammatories
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Inflammatory pain
Most Recent Events
- 04 Sep 2023 Discontinued - Preclinical for Inflammatory pain in China (PO) (Arissa Pharma pipeline, September 2023)
- 28 Jul 2020 No recent reports of development identified for preclinical development in Inflammatory-pain in China (PO)
- 06 Jun 2016 Preclinical trials in Inflammatory pain in China (PO) before June 2016